Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase II study of everolimus in metastatic urothelial cancer

Open access
Milowsky, Matthew I., Iyer, Gopa, Regazzi, Ashley M., Al‐Ahmadie, Hikmat, Gerst, Scott R., Ostrovnaya, Irina, Gellert, Lan L., Kaplan, Rana, Garcia‐Grossman, Ilana R., Pendse, Deepa, Balar, Arjun V., Flaherty, Anne Marie, Trout, Alisa, Solit, David B., Bajorin, Dean F.·2013·BJU International

Abstract

What's known on the subject? and What does the study add?: No recent advances have been made in the treatment of patients with advanced bladder cancer and, to date, targeted therapies have not resulted in an improvement in outcome. The mammalian target of rapamycin pathway has been shown to be up‐regulated in bladder cancer and represents a rational target for therapeutic intervention. In the present phase II study of everolimus, one near‐complete response, one partial response and several minor responses suggest that everolimus possesses biological activity in a subset of patients with bladder cancer. To maximize benefit from targeted agents such as everolimus, the preselection of patients based on molecular phenotype is required. Objective: To assess the efficacy and tolerability of everolimus in advanced urothelial carcimoma ( UC ). Patients and Methods: The present study comprised a single‐arm, non‐randomized study in which all patients received everolimus 10 mg orally once daily continuously (one cycle = 4 weeks). In total, 45 patients with metastatic UC progressing after one to four cytotoxic agents were enrolled between F ebruary 2009 and N ovember 2010 at the M emorial S loan‐ K ettering C ancer C enter. The primary endpoints were 2‐month progression‐free survival ( PFS ) and the safety of everolimus, with the secondary endpoint being the response rate. A S imon minimax two‐stage design tested the null hypothesis that the true two month PFS rate was ≤50%, as opposed to the alternative hypothesis of ≥70%. Results: The most common grade 3/4 toxicities were fatigue, infection, anaemia, lymphopaenia, hyperglycaemia and hypophosphataemia. There were two partial responses in nodal metastases, with one patient achieving a 94% decrease in target lesions and remaining on drug at 26 months. An additional 12 patients exhibited minor tumour regression. There were 23 of 45 (51%) patients who were progression‐free at 2 months with a median (95% CI ) PFS of 2.6 (1.8–3.5) months and a median (95% CI ) overall survival of 8.3 (5.5–12.1) months. No clear association was observed between mammalian target of rapamycin pathway marker expression and 2‐month PFS . Conclusions: Although everolimus did not meet its primary endpoint, one partial response, one near‐complete response and twelve minor regressions were observed. Everolimus possesses meaningful anti‐tumour activity in a subset of patients with advanced UC . Studies aiming to define the genetic basis of everolimus activity in individual responders are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-410x.2012.11720.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 166

Metadata

Authors
Milowsky, M. I., Iyer, G., Regazzi, A. M., Al‐Ahmadie, H., Gerst, S. R., Ostrovnaya, I., Gellert, L. L., Kaplan, R., Garcia‐Grossman, I. R., Pendse, D., Balar, A. V., Flaherty, A. M., Trout, A., Solit, D. B., & Bajorin, D. F.
Venue
BJU International
Publisher
Wiley
Published
2013-04-03
Volume
112
Issue
4
Pages
462-470
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W1725351598
Cited by
166
References
3
FWCI
23.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of everolimus in metastatic urothelial cancer. https://app.cochat.ai/papers/10.1111/j.1464-410x.2012.11720.x
The paper
Milowsky, M. I., Iyer, G., Regazzi, A. M., Al‐Ahmadie, H., Gerst, S. R., Ostrovnaya, I., Gellert, L. L., Kaplan, R., Garcia‐Grossman, I. R., Pendse, D., Balar, A. V., Flaherty, A. M., Trout, A., Solit, D. B., & Bajorin, D. F. (2013). Phase II study of everolimus in metastatic urothelial cancer. BJU International. https://doi.org/10.1111/j.1464-410x.2012.11720.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.